# GSK vs Sanofi: valuation, size and margins compared

URL: https://funkfolio.com/compare/gsk-vs-sny

> GSK and Sanofi side by side: market value, valuation, margins, balance sheet, one-year price change and superinvestor holders.

---

## GSK vs Sanofi

GSK (GSK), health care, and Sanofi (SNY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Sanofi is worth $114.1B on the stock market and GSK $98.7B: Sanofi is valued at 16% more. GSK trades at 17.2 times earnings and Sanofi at 23.6; operating margins in their latest fiscal years were 24.3% and 14.5%. Over the past year GSK's share price has moved +6.42% and Sanofi's -4.48%.

### Key facts

- **GSK market value:** $98.7B
- **Sanofi market value:** $114.1B
- **GSK P/E:** 17.2
- **Sanofi P/E:** 23.6
- **GSK revenue:** $43.4B FY to 2025-12-31
- **Sanofi revenue:** $48.4B FY to 2025-12-31
- **Superinvestors holding both:** 4

Market values as of 18 Nov 2026, 10:47 UTC.

GSK vs Sanofi: every measure side by side

| Measure | GSK | Sanofi |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United Kingdom | France |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $98.7B lower | $114.1B higher |
| Revenue | $43.4B lower | $48.4B higher |
| Earnings | $7.6B lower | $8.7B higher |
| Employees | 66,841 lower | 74,846 higher |
| Total assets | $81.1B lower | $140.7B higher |
| Valuation |  |  |
| P/E | 17.2 lower | 23.6 higher |
| P/S | 2.3 lower | 2.4 higher |
| P/B | — | — |
| Dividend yield | — | — |
| Profitability |  |  |
| Operating margin | 24.3% higher | 14.5% lower |
| Balance sheet |  |  |
| Net assets | $21.7B lower | $79.2B higher |
| Total liabilities | $59.9B lower | $61.1B higher |
| Total debt | $19.2B lower | $20.8B higher |
| Cash on hand | $4.5B lower | $8.5B higher |
| Price change |  |  |
| Today | -2.32% lower | -1.78% higher |
| 1 year | +6.42% higher | -4.48% lower |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: GSK 103.6, Sanofi 91.8.

- GSK (GSK)
- Sanofi (SNY)

GSK and Sanofi share prices over one year, rebased to 100: GSK ends at 103.6, Sanofi at 91.8.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | GSK | SNY |
| --- | --- | --- |
| Nov 28, 2025 | 100.7 | 96.3 |
| Dec 31, 2025 | 103.2 | 93.6 |
| Jan 30, 2026 | 108.6 | 90.8 |
| Feb 27, 2026 | 124.4 | 94.0 |
| Mar 31, 2026 | 116.1 | 93.0 |
| Apr 30, 2026 | 110.1 | 90.0 |
| May 29, 2026 | 106.3 | 84.3 |
| Jun 30, 2026 | 110.3 | 82.4 |
| Jul 31, 2026 | 108.8 | 83.2 |
| Aug 31, 2026 | 105.7 | 85.7 |
| Sep 30, 2026 | 101.3 | 79.6 |
| Oct 30, 2026 | 104.2 | 85.6 |
| Nov 17, 2026 | 103.6 | 91.8 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (4)

- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 1.1% / 0.3%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.5% / 1.2%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.5% / 0.1%
- [Richard Pzena](https://funkfolio.com/gurus/richard-pzena) &lt;0.1% / &lt;0.1%

#### GSK only (7)

- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 0.9%
- [Primecap team](https://funkfolio.com/gurus/primecap) 0.8%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 0.4%
- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 0.3%
- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.2%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) 0.1%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) &lt;0.1%

#### Sanofi only (3)

- [Louis Bacon](https://funkfolio.com/gurus/louis-bacon) 0.5%
- [Sarah Ketterer](https://funkfolio.com/gurus/sarah-ketterer) 0.4%
- [Lee Ainslie](https://funkfolio.com/gurus/lee-ainslie) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": GSK / Sanofi). [Who owns GSK](https://funkfolio.com/stock/GSK/superinvestors) · [Who owns SNY](https://funkfolio.com/stock/SNY/superinvestors)

### More on GSK

- [GSK (GSK) stock page](https://funkfolio.com/stock/GSK)
- [GSK market cap](https://funkfolio.com/stock/GSK/market-cap)
- [GSK revenue](https://funkfolio.com/stock/GSK/revenue)
- [GSK P/E ratio](https://funkfolio.com/stock/GSK/pe-ratio)
- [GSK operating margin](https://funkfolio.com/stock/GSK/operating-margin)
- [GSK total debt](https://funkfolio.com/stock/GSK/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Sanofi

- [Sanofi (SNY) stock page](https://funkfolio.com/stock/SNY)
- [Sanofi market cap](https://funkfolio.com/stock/SNY/market-cap)
- [Sanofi revenue](https://funkfolio.com/stock/SNY/revenue)
- [Sanofi P/E ratio](https://funkfolio.com/stock/SNY/pe-ratio)
- [Sanofi operating margin](https://funkfolio.com/stock/SNY/operating-margin)
- [Sanofi total debt](https://funkfolio.com/stock/SNY/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### GSK against its closest peers

- [GSK vs HCA Healthcare](https://funkfolio.com/compare/gsk-vs-hca)
- [GSK vs CVS Health](https://funkfolio.com/compare/cvs-vs-gsk)
- [GSK vs Moderna](https://funkfolio.com/compare/gsk-vs-mrna)
- [GSK vs Regeneron Pharmaceuticals](https://funkfolio.com/compare/gsk-vs-regn)

#### Sanofi against its closest peers

- [Sanofi vs Moderna](https://funkfolio.com/compare/mrna-vs-sny)
- [Sanofi vs McKesson](https://funkfolio.com/compare/mck-vs-sny)
- [Sanofi vs CVS Health](https://funkfolio.com/compare/cvs-vs-sny)
- [Sanofi vs Stryker](https://funkfolio.com/compare/sny-vs-syk)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, GSK or Sanofi?**

By market value, Sanofi is the larger: $114.1B against $98.7B for GSK. By revenue in its latest fiscal year, Sanofi is the larger: $48.4B against $43.4B for GSK.

**Which has the higher P/E ratio?**

Sanofi: 23.6, against 17.2 for GSK. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

GSK: 24.3%, against 14.5% for Sanofi. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has more debt?**

Sanofi: $20.8B, against $19.2B for GSK. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both GSK and Sanofi?**

In their latest 13F filings, Dodge & Cox team, Charles Brandes (founder), Ken Fisher and Richard Pzena hold both.

### Cite this page

Funkfolio, “GSK vs Sanofi”, data as of 18 November 2026. https://funkfolio.com/compare/gsk-vs-sny

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
